Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pediatric Antidepressant Research Hearing

This article was originally published in The Pink Sheet Daily

Executive Summary

The House Energy & Commerce/Oversight Subcommittee will hold a hearing on publication and disclosure issues in antidepressant pediatric clinical trials July 20

You may also be interested in...

GSK Handling Of Paxil Data On Pediatric Use Is Subject Of N.Y. Lawsuit

The state attorney general alleges that GSK failed to publish information about the safety and efficacy of Paxil in children. The lawsuit seeks disgorgement of profits. GSK maintains that it has publicly communicated the data from its pediatric studies.

FDA Antidepressant Data Was Fully Disclosed, Agency Tells Congress

Although there was internal disagreement on the implications of pediatric antidepressant data, all information was reviewed publicly, the agency maintains in a letter to the House Energy & Commerce/Oversight Subcommittee.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts